Arrowhead Pharmaceuticals (ARWR) News Today $60.21 +1.18 (+2.00%) Closing price 04:00 PM EasternExtended Trading$59.61 -0.60 (-0.99%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Arrowhead Pharmaceuticals Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce TriglyceridesOctober 27 at 11:36 AM | businesswire.comArrowhead Pharmaceuticals, Inc. $ARWR Stock: Washington Trust Advisors Inc. Grows StakeOctober 24, 2026 | marketbeat.comAssenagon Asset Management S.A. Sells 198,659 Shares of Arrowhead Pharmaceuticals, Inc. $ARWROctober 24, 2026 | marketbeat.comArrowhead Pharmaceuticals And 2 Biotech Stocks To OwnOctober 24, 2026 | finance.yahoo.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsOctober 23, 2026 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Has Average Price Target of $99.07October 23, 2026 | marketbeat.comFY2031 Earnings Forecast for ARWR Issued By HC WainwrightOctober 18, 2026 | americanbankingnews.comArrowhead Pharmaceuticals (ARWR) Gets a Buy from Piper SandlerOctober 17, 2026 | theglobeandmail.comUBS Group Upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to "Strong-Buy"October 17, 2026 | marketbeat.comArrowhead Pharmaceuticals (ARWR) Receives a New Rating from UBSOctober 16, 2026 | theglobeandmail.comArrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?October 16, 2026 | finance.yahoo.comEquities Analysts Issue Forecasts for ARWR FY2031 EarningsOctober 16, 2026 | marketbeat.comARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS DiseasesOctober 15, 2026 | msn.comUBS Group Initiates Coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR)October 15, 2026 | marketbeat.comArrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New PlatformOctober 15, 2026 | seekingalpha.comArrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reaffirmed at Chardan CapitalOctober 15, 2026 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Reaffirmed as "Buy" by HC WainwrightOctober 15, 2026 | marketbeat.comArrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline TranscriptOctober 14, 2026 | seekingalpha.comArrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT StudyOctober 14, 2026 | marketbeat.comArrowhead Reports Positive Phase 1/2a Data For Alzheimer's Candidate ARO-MAPTOctober 14, 2026 | rttnews.comArrowhead jumps as breakthrough Alzheimer’s drug clears brain barrierOctober 14, 2026 | finance.yahoo.comArrowhead Pharmaceuticals Reports Up to 73% Tau Reduction in ARO-MAPT TrialOctober 14, 2026 | finance.yahoo.comArrowhead spikes after early-stage trial data for Alzheimer’s diseaseOctober 14, 2026 | seekingalpha.comArrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline - SlideshowOctober 14, 2026 | seekingalpha.comArrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy VolunteersOctober 14, 2026 | businesswire.comAnalysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Humana (HUM) and Arrowhead Pharmaceuticals (ARWR)October 13, 2026 | theglobeandmail.comArrowhead’s Plozasiran Trial Completion Signals a Pivotal Moment for ARWR InvestorsOctober 9, 2026 | tipranks.comArrowhead’s Plozasiran Hits Phase 3 Completion: What Investors Should Watch NextOctober 8, 2026 | tipranks.comArrowhead Pharmaceuticals, Inc. (ARWR)October 7, 2026 | finance.yahoo.comArrowhead Flat on FDA NodOctober 7, 2026 | baystreet.caArrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe HypertriglyceridemiaOctober 7, 2026 | marketscreener.comMArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average - Here's WhyOctober 6, 2026 | marketbeat.comArrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million VoucherOctober 2, 2026 | seekingalpha.comArrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesSeptember 29, 2026 | marketscreener.comMArrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other TauopathiesSeptember 29, 2026 | businesswire.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Has Consensus Price Target of $98.31 According to AnalystsSeptember 28, 2026 | marketbeat.comArrowhead’s Plozasiran Trial Completion Marks a Key Catalyst in the Triglyceride MarketSeptember 25, 2026 | tipranks.comARWR stock: Goldman Sachs resumes coverage with $74 target as clinical catalysts nearSeptember 24, 2026 | msn.comArrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still HoldsSeptember 19, 2026 | finance.yahoo.comNot a 'gangbusters launch' — Arrowhead predicts slow burn to $3-$4B peak for Redemplo, highlights 'massive pipeline'September 16, 2026 | msn.comArrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeptember 16, 2026 | seekingalpha.comARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?September 16, 2026 | finance.yahoo.comARWR stock on track for worst day in over a year despite positive early-stage data for cholesterol drug — retail dismisses 'sell the news' reactionSeptember 15, 2026 | msn.comArrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comArrowhead Pharmaceuticals Announces Interim Topline Clinical Data for Aro-Dimer-Pa Phase 1/2A Clinical TrialSeptember 15, 2026 | marketscreener.comMArrowhead Pharmaceuticals Stock Falls 9% After Announcement Of ARO-DIMER-PA Trial DataSeptember 15, 2026 | rttnews.comArrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaSeptember 15, 2026 | businesswire.comArrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026September 8, 2026 | finance.yahoo.comArrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 MillionSeptember 6, 2026 | fool.com Arrowhead Pharmaceuticals Media Mentions By Week Arrowhead Pharmaceuticals Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.980.68▲Average Healthcare News Sentiment Arrowhead Pharmaceuticals News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼78▲ARWR Articles Average Week Arrowhead Pharmaceuticals Trends on MarketBeatThis week vs. last weekNew Followers1-50%Searches1Page Views3,445-13% Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Roivant Sciences News Genmab A/S News Incyte News United Therapeutics News BioNTech News Insmed News Exelixis News Ascendis Pharma A/S News Halozyme Therapeutics News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Arrowhead Pharmaceuticals dated 10/27/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredElon gets it. Do you?Moderna shares surged almost 200% in a single day after a successful phase 3 trial for its cancer drug, while ...Porter & Company | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
